Defence Therapeutics Inc. (DTCFF)
| Previous Close | 3.9400 |
| Open | 4.3880 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 4.0300 - 4.3880 |
| 52 Week Range | 2.5000 - 6.4078 |
| Volume | |
| Avg. Volume | 1,231 |
| Market Cap | 141.701M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1120 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Defence's Accum(TM)-HPV Vaccine Formulation (AccuVAC-PT009) Activates a 36-Fold Higher Humoral Response Compared to Gardasil-9
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the development of AccuVAC-PT009, a new protein-based HPV vaccine, leading to a humoral response bypassing Gardasil-9 (Merck) immunogenicity in animals.ACCUMTM is a platform technology 100% owned by Defence Therapeutics. ACCUMTM is
- Newsfile
Defence Therapeutics Achieves a Major Milestone and Begins IND-Enabling Testing of Its AccuTOX Lead Compound Against Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the start of its final step in GLP studies on its lead anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited prior to initiate its Phase I trial in breast cancer patients. Eurofins Advinus Limited is a leading Drug Discovery ..
- Newsfile
Defence Therapeutics Accum(TM) Boosts by 9-Fold the Delivery Effectiveness of the CRISPR/Cas9 Protein to Target Cells
Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company focused on the development of vaccines and therapeutics against cancer and infectious diseases, is pleased to announce that its AccumTM platform can potently enhance Cas9 delivery in target cells, which would have a significant positive impact on the CRISPR industry. The CRISPR technology offers the potential t
